On analyst had recently mentioned in an article on seekingalpha that Senesco stock has suffered over the past year 'for no instantly recognizable reason'. He had concluded by saying that the market currently values the company at a discount to its peers, despite consistently positive trial data. Regarding the technology being developed by Senesco, he had said 'the science behind SNS01-T is a revolutionary, cutting-edge approach to cancer treatment, and if proven effective could be applied to a range of other diseases. Upcoming catalysts including cohort three and cohort four results could reverse investor sentiment, and in turn, initiate a market revaluation of Senesco.' The company will announce the results of the trials soon. It had announced that it will make two presentations on SNS01-T for blood-borne cancer care at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition to be held from December 7-10th in New Orleans. The management stated that the company will provide an update on the current results of the trial, and also make an oral presentation of new results with SNS01T in non-clinical studies. Though the FDA approval etc. may take a couple of years, the preliminary results of the trials have been encouraging. If the upcoming results are as encouraging on tolerability & efficacy, then the stock may start an uptrend. It is important to note that the main purpose of the trials so far has been to test the safety and tolerability of the drug, and exploring whether SNS01T is an effective treatment for multiple myeloma, mantle cell lymphoma and diffuse large B cell lymphoma is the second objective. It is obviously good to invest in a development stage company before the stock takes of due to some important event. Many analysts are already positive on the stock, based on expected positive outcome of the trials.
